Strategic Alternatives

How to Build and Sell a Biotech in 2024

Jul 8, 2024
Guest
Roberto Bellini
Guest
Mark McKenna
Guest
Bill Meury
Guest
Dan O'Connor
CEOs who sold biotechs worth $29bn share insights on M&A. They discuss building strong organizations, understanding value, navigating FTC regulations, analyzing legal principles, and strategic considerations for biotech M&A in 2024.
Ask episode
Chapters
Transcript
Episode notes
1
Intro
00:00 • 2min
2
Building and Navigating a Biotech Company for Potential Acquisition
01:37 • 16min
3
Understanding Intrinsic and Market Value of a Biotech Business
18:00 • 2min
4
Analysis of FTC and Anti-trust Regulations in Biotech Sector
20:12 • 2min
5
Analyzing Legal Principles and Macro Factors in Business Acquisition
21:54 • 3min
6
Strategic Considerations in Biotech M&A
24:26 • 9min
7
Investor Priorities in Biotech Acquisitions
33:15 • 2min